Akili has achieved great success in the research and design of its digital medicine platform, a novel approach using high-quality action video game experiences to treat cognitive dysfunction. Akili needed experienced investors and unprecedented legal support to secure financing for its innovative treatments which could yield enormous benefits for patients, including children and adolescents with ADHD.


If approved, Akili’s lead product candidate, AKL-T01, will be the first prescription digital treatment for pediatric ADHD. The firm assembled an experienced and driven cross-office team from its Technology & Life Sciences Group to guide Akili through a seamless round of financing.


With the proceeds from the financing, Akili will advance its pipeline of digital prescription treatments, including AKL-T01, through key regulatory milestones and towards commercial launch. In addition, Akili is now able to further expand its product pipeline into digital treatments for depression and multiple sclerosis.